Trending...
- Root Canal Specialist In Frederick Maryland Joins Pearlfection Dentistry
- City Council Candidates Unite Behind "Common Sense Contract with NYC"
- Steel Oak Coffee Launches First Interactive Coffee Flavor Wheel for Consumers
ANN ARBOR, Mich., Jan. 13, 2021 /PRNewswire/ -- EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization. In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies. Amgen is a world leader in the treatment of autoimmune disorders, with a portfolio that includes both innovative medicines, including Otezla® and Enbrel®, and biosimilar products, such as AMGEVITA® (a biosimilar to Humira®) and AVSOLA® (a biosimilar to Remicade®).
More on Michimich.com
About EVOQ Therapeutics
EVOQ Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens for recognition by the immune system. www.evoqtherapeutics.com
SOURCE EVOQ Therapeutics
Related Links
https://www.evoqtherapeutics.com
More on Michimich.com
- Northville Pickleball Club Opens, Michigan's Premier Indoor Pickleball Destination
- Florida International University: "Psychiatry: An Industry of Death" Traveling Exhibit Educates Students on Mental Health Abuse
- CCHR: VA's Psychiatric Treatments Betray Veterans, Fuel Suicide and Death
- Integris Composites Named Armor Partner for U.S. Army's XM30 Combat Vehicle
- Jaipur Countryside, 4-Star Comfort: $199 for Two— All-Inclusive with Meals + Transfers at Heritage Hotel Savista
About EVOQ Therapeutics
EVOQ Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens for recognition by the immune system. www.evoqtherapeutics.com
SOURCE EVOQ Therapeutics
Related Links
https://www.evoqtherapeutics.com
Filed Under: Business
0 Comments
Latest on Michimich.com
- Probate Shepherd® Announces a New Member Probate Attorney in The Woodlands, TX
- Probate Shepherd® Announces a New Member Probate Attorney in Conroe, TX
- Taraji P. Henson's Boris Lawrence Henson Foundation (BLHF) Announce 5th Annual Can We Talk? Arts & Wellness Summit and "i AM The Table Benefit Brunch
- Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets
- Mensa Members Put Brainpower to Work for Literacy
- Rep. Gina H. Curry and Dr. Conan Tu Inspire at Kopp Foundation for Diabetes Hybrid Fundraising Gala and National Leadership Forum
- Elliott Expands Investment Services with Naviark App Launch
- Roofman USA Proudly Serves Warren, Trenton, Belleville, and Monroe with Expert Roofing Services
- Understanding Roofing Warranties: Key Details Ann Arbor Homeowners Should Know
- Wilderness Construction Highlights Top 3 Ways Entry Doors Can Boost Home Security and Value
- Safety, Self-Defense & Life Skills: JMAC Highlights the Benefits of Martial Arts Training
- Restoration Dental Introduces YOMI Robot for High-Precision Implant Surgery in Oklahoma
- Elite Rooter Creates Jobs and Expands Reach Coast to Coast with New Tampa, FL Plumbing Location
- "Super Leftist", the new poetry book by Pierre Gervois
- RNHA FL Unveils Bold New Leadership Ahead of 2026 Elections
- ASI Honors Client Achievements at 27th Annual iNNOVATIONS Conference
- Lightship Security and the OpenSSL Corporation Submit OpenSSL 3.5.4 for FIPS 140-3 Validation
- WADA AWARDS - where Diamonds melt into glamour
- First Nations Bank of Canada Partners with KYC2020 to Strengthen AML Screening and Monitoring Capabilities
- Bitcoin will still be the leader in the cryptocurrency market in 2025, and WOA Mining enthusiasts will earn passive income